Myelodysplastic syndrome (MDS; myelodysplasia, preleukaemia)
Bone marrow failure / clonal · Haematology / Oncology
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Clonal stem-cell disorders causing ineffective haematopoiesis -> cytopenias with dysplastic, usually hypercellular marrow, and risk of AML transformation. Older adults with unexplained anaemia +/- neutropenia/thrombocytopenia. ED role: manage cytopenic complications (anaemia, infection, bleeding) and refer; distinguish from reversible causes.
Red flags
- Febrile neutropenia (treat as sepsis immediately)
- Rising blast percentage / circulating blasts (AML transformation)
- Severe thrombocytopenia with bleeding
- Rapidly progressive pancytopenia
- New symptomatic severe anaemia
Assessment
Differential diagnosis
- Reversible cytopenias: B12/folate deficiency, copper deficiency, alcohol, drugs, viral (HIV), autoimmune
- Aplastic anaemia / PNH
- Acute leukaemia (blasts >=20%)
- Myelofibrosis / MDS-MPN overlap (e.g. CMML)
- Marrow infiltration by lymphoma/carcinoma
Investigations
- FBC + reticulocytes + blood film (oval macrocytes, hypogranular/hypolobated neutrophils - pseudo-Pelger-Huet, blasts)
- B12, folate, ferritin, TFTs, LFTs, copper, HIV (exclude reversible causes) before labelling MDS
- Bone marrow aspirate + trephine: dysplasia, blast %, ring sideroblasts; cytogenetics (e.g. del(5q), -7); molecular panel
- Reticulocyte count, haptoglobin/LDH (exclude haemolysis)
- Risk score: IPSS-R / IPSS-M (prognosis and treatment)
- Group & screen, viral serology (pre-transfusion/transplant)
Management
- Exclude and correct reversible causes of cytopenia first
- Manage acute complications: transfuse symptomatic anaemia; treat neutropenic fever as sepsis; manage bleeding from thrombocytopenia
- Risk-stratify (IPSS-R) - low-risk: supportive care +/- ESA; high-risk: hypomethylating agent or transplant assessment
- Iron chelation if chronically transfusion-dependent and ongoing need (low-risk, ferritin very high)
- del(5q) syndrome: lenalidomide
- Assess allogeneic transplant eligibility in higher-risk, fit patients
- Vaccinate; counsel on infection/bleeding precautions
Drugs & doses
Transfuse packed red cells for symptomatic anaemia (restrictive threshold); platelets for bleeding/very low counts
Erythropoiesis-stimulating agent (epoetin/darbepoetin) for low-risk anaemia with low endogenous EPO [verify local dose]
Azacitidine 75 mg/m2 SC/IV daily x7 days every 28 days (higher-risk MDS) [verify local dose]
Lenalidomide 10 mg PO once daily (del(5q) MDS) [verify local dose]
Iron chelation - deferasirox per weight if transfusion iron overload [verify local dose]
Broad-spectrum antibiotics per neutropenic sepsis protocol for febrile neutropenia
Allogeneic stem cell transplant - only curative option (eligible higher-risk patients)
Disposition
Febrile neutropenia / severe bleeding / symptomatic anaemia -> admit. Stable -> outpatient haematology for marrow, risk scoring and treatment.
Complications & pitfalls
- Transformation to acute myeloid leukaemia
- Infection from neutropenia (leading cause of death)
- Bleeding from thrombocytopenia
- Transfusional iron overload
- Transfusion dependence
Exam pearls
- Always exclude B12/folate/copper deficiency, HIV and drugs before diagnosing MDS - these are reversible
- IPSS-R/IPSS-M drives management: supportive for low-risk, hypomethylating/transplant for high-risk
- A febrile neutropenic MDS patient needs antibiotics within 1 hour - do not wait for cultures
- del(5q) MDS responds well to lenalidomide
- Macrocytic anaemia in an older adult with a normal B12/folate deserves a film and marrow
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.